NLS and Kadimastem move forward with merger plans
ZURICH and NESS ZIONA, Israel - Shareholders of Kadimastem Ltd. (TASE: KDST), a cell therapy company currently valued at $18.19 million, have approved a merger with Swiss biopharmaceutical firm NLS ...
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...
Diagnostic Imaging Agent Market Projected To Hit USD 57.18 Billion By 2032, At A Exceptional CAGR 5.51%
Diagnostic Imaging Agent Market The chronic diseases such as cancer, cardiovascular diseases is a factor driving the growth of the Global D ...
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system ...
‘Innovation from India will bring critical access to affordable healthcare’: Padma awardee Pankaj Patel
The Ahmedabad -based Patel, whose Zydus Group runs a chain of multi-specialty hospitals, further said, “We are taking a leap ...
Innovation from India to empower people to lead healthier life: Zydus' Patel on selection for Padma
Zydus Lifesciences Chairman Pankaj R Patel has been awarded the prestigious Padma Bhushan for his contributions to the ...
"Honoured to receive this recognition and consider myself fortunate": Zydus Lifesciences Chairman thanks GoI for Padma Bhushan honour
Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday expressed his gratitude upon being bestowed with one of Indias ...